Hypofractionated radiation treatment in the management of breast cancer

Apar Gupta, Nisha Ohri, Bruce Haffty

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: The standard treatment for early-stage breast cancer is breast conservation therapy, consisting of breast conserving surgery followed by adjuvant radiation treatment (RT). Conventionally-fractionated whole breast irradiation (CF-WBI) has been the standard RT regimen, but recently shorter courses of hypofractionated whole breast irradiation (HF-WBI) have been advocated for patient convenience and reduction in healthcare costs and resources. Areas covered: This review covers the major randomized European and Canadian trials comparing HF-WBI to CF-WBI with long-term follow-up, as well as additional recently closed randomized trials that further seek to define the applicability of HF-WBI in clinical practice. Randomized data is summarized in terms of clinical utility and for a variety of clinical applications. Recently published consensus guidelines and practical implementation of HF-WBI including its broader effect on the healthcare system are reviewed. Finally, an assessment of the emerging evidence in support of hypofractionation for locally advanced disease is presented. Expert commentary: HF-WBI has replaced CF-WBI as the accepted standard of care in most women with early-stage breast cancer who do not require regional nodal irradiation. Early data supports the continued study of hypofractionation in the locally advanced setting, however broad adoption awaits longer follow-up and additional data from ongoing clinical trials.

Original languageEnglish (US)
Pages (from-to)793-803
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume18
Issue number8
DOIs
StatePublished - Aug 3 2018

Fingerprint

Breast
Radiation
Breast Neoplasms
Segmental Mastectomy
Therapeutics
Standard of Care
Health Care Costs
Clinical Trials
Guidelines
Delivery of Health Care

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Oncology

Cite this

@article{d997860724fc41259cf847bc62c679ba,
title = "Hypofractionated radiation treatment in the management of breast cancer",
abstract = "Introduction: The standard treatment for early-stage breast cancer is breast conservation therapy, consisting of breast conserving surgery followed by adjuvant radiation treatment (RT). Conventionally-fractionated whole breast irradiation (CF-WBI) has been the standard RT regimen, but recently shorter courses of hypofractionated whole breast irradiation (HF-WBI) have been advocated for patient convenience and reduction in healthcare costs and resources. Areas covered: This review covers the major randomized European and Canadian trials comparing HF-WBI to CF-WBI with long-term follow-up, as well as additional recently closed randomized trials that further seek to define the applicability of HF-WBI in clinical practice. Randomized data is summarized in terms of clinical utility and for a variety of clinical applications. Recently published consensus guidelines and practical implementation of HF-WBI including its broader effect on the healthcare system are reviewed. Finally, an assessment of the emerging evidence in support of hypofractionation for locally advanced disease is presented. Expert commentary: HF-WBI has replaced CF-WBI as the accepted standard of care in most women with early-stage breast cancer who do not require regional nodal irradiation. Early data supports the continued study of hypofractionation in the locally advanced setting, however broad adoption awaits longer follow-up and additional data from ongoing clinical trials.",
author = "Apar Gupta and Nisha Ohri and Bruce Haffty",
year = "2018",
month = "8",
day = "3",
doi = "https://doi.org/10.1080/14737140.2018.1489245",
language = "English (US)",
volume = "18",
pages = "793--803",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "8",

}

Hypofractionated radiation treatment in the management of breast cancer. / Gupta, Apar; Ohri, Nisha; Haffty, Bruce.

In: Expert Review of Anticancer Therapy, Vol. 18, No. 8, 03.08.2018, p. 793-803.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Hypofractionated radiation treatment in the management of breast cancer

AU - Gupta, Apar

AU - Ohri, Nisha

AU - Haffty, Bruce

PY - 2018/8/3

Y1 - 2018/8/3

N2 - Introduction: The standard treatment for early-stage breast cancer is breast conservation therapy, consisting of breast conserving surgery followed by adjuvant radiation treatment (RT). Conventionally-fractionated whole breast irradiation (CF-WBI) has been the standard RT regimen, but recently shorter courses of hypofractionated whole breast irradiation (HF-WBI) have been advocated for patient convenience and reduction in healthcare costs and resources. Areas covered: This review covers the major randomized European and Canadian trials comparing HF-WBI to CF-WBI with long-term follow-up, as well as additional recently closed randomized trials that further seek to define the applicability of HF-WBI in clinical practice. Randomized data is summarized in terms of clinical utility and for a variety of clinical applications. Recently published consensus guidelines and practical implementation of HF-WBI including its broader effect on the healthcare system are reviewed. Finally, an assessment of the emerging evidence in support of hypofractionation for locally advanced disease is presented. Expert commentary: HF-WBI has replaced CF-WBI as the accepted standard of care in most women with early-stage breast cancer who do not require regional nodal irradiation. Early data supports the continued study of hypofractionation in the locally advanced setting, however broad adoption awaits longer follow-up and additional data from ongoing clinical trials.

AB - Introduction: The standard treatment for early-stage breast cancer is breast conservation therapy, consisting of breast conserving surgery followed by adjuvant radiation treatment (RT). Conventionally-fractionated whole breast irradiation (CF-WBI) has been the standard RT regimen, but recently shorter courses of hypofractionated whole breast irradiation (HF-WBI) have been advocated for patient convenience and reduction in healthcare costs and resources. Areas covered: This review covers the major randomized European and Canadian trials comparing HF-WBI to CF-WBI with long-term follow-up, as well as additional recently closed randomized trials that further seek to define the applicability of HF-WBI in clinical practice. Randomized data is summarized in terms of clinical utility and for a variety of clinical applications. Recently published consensus guidelines and practical implementation of HF-WBI including its broader effect on the healthcare system are reviewed. Finally, an assessment of the emerging evidence in support of hypofractionation for locally advanced disease is presented. Expert commentary: HF-WBI has replaced CF-WBI as the accepted standard of care in most women with early-stage breast cancer who do not require regional nodal irradiation. Early data supports the continued study of hypofractionation in the locally advanced setting, however broad adoption awaits longer follow-up and additional data from ongoing clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85050295973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050295973&partnerID=8YFLogxK

U2 - https://doi.org/10.1080/14737140.2018.1489245

DO - https://doi.org/10.1080/14737140.2018.1489245

M3 - Review article

VL - 18

SP - 793

EP - 803

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 8

ER -